Pavel Marianne E, Hassler Gerda, Baum Ulrich, Hahn Eckhart G, Lohmann Tobias, Schuppan Detlef
Department of Medicine I, University Hospital Erlangen-Nuernberg, Ulmensweg 18, 91054 Erlangen, Germany.
Clin Endocrinol (Oxf). 2005 Apr;62(4):434-43. doi: 10.1111/j.1365-2265.2005.02238.x.
The growth behaviour of well-differentiated neuroendocrine carcinomas of the gastro-entero-pancreatic system varies greatly and parameters predicting their prognosis are lacking. The aim of our study was to investigate whether tumour growth could be correlated with the release of proangiogenic factors into the circulation.
Circulating vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), basic fibroblast growth factor (bFGF) and angiogenin were measured in 38 patients with advanced neuroendocrine carcinomas and compared to healthy age-matched controls. In 20 patients, angiogenic cytokine levels were measured at consecutive time points and correlated to tumour progression as assessed by abdominal CT scan, MRI and chromogranin A levels.
VEGF levels were elevated in patients compared to controls (P < 0.002) and clearly associated with tumour progression (P < 0.005). Angiogenin levels were significantly higher in patients than in controls (P < 0.003), while high IL-8 levels were predictive of shorter survival. Angiogenin and bFGF levels were correlated neither with tumour growth nor with patient survival.
VEGF and IL-8 are associated with tumour progression and might qualify as markers of prognosis and therapy control in patients with neuroendocrine carcinomas. Our results support the notion that specific anti-angiogenic therapies should be evaluated in neuroendocrine carcinoma patients.
胃肠胰系统高分化神经内分泌癌的生长行为差异很大,且缺乏预测其预后的参数。我们研究的目的是调查肿瘤生长是否与促血管生成因子释放至循环系统有关。
检测了38例晚期神经内分泌癌患者循环血管内皮生长因子(VEGF)、白细胞介素-8(IL-8)、碱性成纤维细胞生长因子(bFGF)和血管生成素水平,并与年龄匹配的健康对照者进行比较。在20例患者中,连续时间点测量血管生成细胞因子水平,并与通过腹部CT扫描、MRI和嗜铬粒蛋白A水平评估的肿瘤进展相关联。
与对照组相比,患者的VEGF水平升高(P < 0.002),且与肿瘤进展明显相关(P < 0.005)。患者的血管生成素水平显著高于对照组(P < 0.003),而高IL-8水平预示生存期较短。血管生成素和bFGF水平与肿瘤生长及患者生存均无相关性。
VEGF和IL-8与肿瘤进展相关,可能可作为神经内分泌癌患者预后和治疗控制的标志物。我们的结果支持在神经内分泌癌患者中评估特定抗血管生成疗法的观点。